CO5251464A1 - Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina - Google Patents

Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina

Info

Publication number
CO5251464A1
CO5251464A1 CO00095239A CO00095239A CO5251464A1 CO 5251464 A1 CO5251464 A1 CO 5251464A1 CO 00095239 A CO00095239 A CO 00095239A CO 00095239 A CO00095239 A CO 00095239A CO 5251464 A1 CO5251464 A1 CO 5251464A1
Authority
CO
Colombia
Prior art keywords
alkyl
oxazolil
tiazolil
uncle
rent
Prior art date
Application number
CO00095239A
Other languages
English (en)
Inventor
Kyoung S Kim
S David Kimball
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,511 external-priority patent/US6262096B1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO5251464A1 publication Critical patent/CO5251464A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Un compuesto de la formula I<EMI FILE="00095239_1" ID="1" IMF=JPEG >y enantiómeros, diasterómeros y sales farmacéuticamente aceptables del mismo, caracterizado porqueR es alquilo;R1 y R2 son cada uno independientemente hidrógeno o alquilo;R3 es hidrógeno o alquilo, y R4 es hidrógeno o alquilo sibstituido con uno o dos grupos hidroxi o un grupo NR5R6, o R3 y R4 se toman conjuntamente con el átomo de nitrógeno al cual están unidos para formar un anillo heterocíclico de 4 a 7 miembros, en donde R3R4 se representa por (CH2)n-, donde n es un número entero de 3, 4, 4 ó 6;R5 y R6 son cada uno independientemente hidrógeno, alquilo, alquilo substituido, cicloalquilo o cicloalquilo substituido, o R5 y R6 se toman conjuntamente con el átomo de nitrógeno al cual están unidos para formar un anillo heterocíclico de 4 a 7 miembros en donde R5R6 se representa por -(CH2)m-, donde m es un número entero de 3,4, 5 ó 6; yX es CH o N.
CO00095239A 1999-12-15 2000-12-14 Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina CO5251464A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/464,511 US6262096B1 (en) 1997-11-12 1999-12-15 Aminothiazole inhibitors of cyclin dependent kinases
US09/616,629 US6214852B1 (en) 1998-10-21 2000-07-26 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Publications (1)

Publication Number Publication Date
CO5251464A1 true CO5251464A1 (es) 2003-02-28

Family

ID=27041009

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00095239A CO5251464A1 (es) 1999-12-15 2000-12-14 Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina

Country Status (22)

Country Link
US (1) US6214852B1 (es)
EP (1) EP1240165B1 (es)
JP (1) JP2003525872A (es)
KR (1) KR20020067547A (es)
CN (1) CN1433415A (es)
AT (1) ATE294800T1 (es)
AU (1) AU774381B2 (es)
CA (1) CA2394544A1 (es)
CO (1) CO5251464A1 (es)
CZ (1) CZ20022013A3 (es)
DE (1) DE60019964T2 (es)
DK (1) DK1240165T3 (es)
EE (1) EE200200306A (es)
ES (1) ES2241678T3 (es)
HU (1) HUP0300974A3 (es)
PE (1) PE20010932A1 (es)
PL (1) PL364884A1 (es)
PT (1) PT1240165E (es)
SI (1) SI20975B (es)
TW (1) TWI265930B (es)
UY (1) UY26480A1 (es)
WO (1) WO2001044241A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) * 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
EA007392B1 (ru) * 2001-07-19 2006-10-27 Фармация Италия С.П.А. Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств
EP1724270A3 (en) * 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
ES2183734B1 (es) * 2001-08-02 2004-06-16 Consejo Sup. Investigaciones Cientificas Derivados de 4-4'-bipiridil-2-2'-bisoxazoles y 4-4'-bipiridil-2-2'-bistiazoles como agentes antineoplasicos.
BR0211626A (pt) * 2001-08-03 2004-08-24 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de doenças, distúrbios, sìndromes e condições
EP1417188A1 (en) * 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
DE10300124A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Verfahren zur Herstellung von Arylalkinen
WO2005012875A2 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US20080188524A1 (en) * 2006-10-25 2008-08-07 Martin Augustin Methods of treating pain
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
LT2760860T (lt) * 2011-09-28 2017-03-10 Euro-Celtique S.A. Azoto garstyčių dariniai
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) * 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
CA1201431A (en) 1981-12-17 1986-03-04 Daiei Tunemoto .beta.-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF
TW205041B (es) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
US5491157A (en) 1993-05-10 1996-02-13 Eastman Kodak Company Method and composition for the prevention, control and amelioration of soilborne fungi and disease caused thereby
IL112721A0 (en) 1994-03-10 1995-05-26 Zeneca Ltd Azole derivatives
JPH10510258A (ja) 1994-12-09 1998-10-06 藤沢薬品工業株式会社 セフェム化合物およびその医薬用途
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
AUPN801196A0 (en) 1996-02-12 1996-03-07 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds and pharmaceutical use thereof
YU22400A (sh) 1997-10-27 2003-08-29 Agouron Pharmaceuticals Inc. Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents

Also Published As

Publication number Publication date
DK1240165T3 (da) 2005-08-08
ATE294800T1 (de) 2005-05-15
TWI265930B (en) 2006-11-11
CZ20022013A3 (cs) 2003-03-12
CN1433415A (zh) 2003-07-30
KR20020067547A (ko) 2002-08-22
ES2241678T3 (es) 2005-11-01
EE200200306A (et) 2003-06-16
DE60019964D1 (en) 2005-06-09
US6214852B1 (en) 2001-04-10
CA2394544A1 (en) 2001-06-21
AU774381B2 (en) 2004-06-24
WO2001044241A1 (en) 2001-06-21
EP1240165B1 (en) 2005-05-04
SI20975B (sl) 2006-04-30
AU1950601A (en) 2001-06-25
UY26480A1 (es) 2001-07-31
HUP0300974A2 (hu) 2003-08-28
PT1240165E (pt) 2005-09-30
SI20975A (sl) 2003-02-28
HUP0300974A3 (en) 2009-03-30
PL364884A1 (en) 2004-12-27
JP2003525872A (ja) 2003-09-02
DE60019964T2 (de) 2006-04-27
EP1240165A1 (en) 2002-09-18
PE20010932A1 (es) 2001-11-18

Similar Documents

Publication Publication Date Title
CO5251464A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
ES2188280T3 (es) Acetales heteroaril-ciclicos.
RS51047B (sr) Derivati 4-tetrazolil-4-fenilpiperidina za lečenje bola
HUP0400828A2 (hu) Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DK1260512T3 (da) Hidtil ukendte, cykliske amidderivater
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200600509A1 (ru) Соединения пиримидотиофена
CO5261565A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
CO5180629A1 (es) Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas
CO5271690A1 (es) Derivados de pirimidina
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
ME00411B (me) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
MXPA02002505A (es) Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos.
HUP0000434A2 (hu) 1,4-Szubsztituált gyűrűs aminszármazékok
HUP0204587A2 (en) 6-position substituted indoline, production and use thereof as a medicament
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
CO5320599A1 (es) Inhibidores no peptidilicos de la union a las celulas depen dientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
EP1642880A4 (en) PROTEIN INHIBITOR OF THE HSP90 FAMILY
CO5251427A1 (es) Oxazolidinonas que tienen la fucion de sulfoximina
AR029499A1 (es) Derivados de pirrolidina, farmaceuticamente activos, aplicables en el tratamiento y/o prevencion de partos y/o nacimientos prematuros y/o dismenorrea, uso de dichos derivados en la preparacion de composiciones farmaceuticas para dichos tratamientos y proceso de preparacion de los derivados mencionad
HUP0203976A2 (hu) Adenozin a3 receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FA Application withdrawn